Replies to post #188787 on Biotech Values

[DewDiligence]

JNJ acquires (private) XO1 Ltd to develop anticoagulant, Ichorcumab:

http://finance.yahoo.com/news/janssen-acquires-xo1-limited-080000722.html

Financial terms have not been disclosed.

[iwfal]

Ichorcumab, an anticoagulant with potentially substantially lower bleeding risk, resurfaces as JNJ-375 2 years after Jansen bought out original company. (It hasn't been in their pipeline charts...)

http://isthcongressdaily.org/improving-therapeutic-index-jnj-375-novel-long-acting-exosite-1-thrombin-inhibitor-animal-models/

H/t @mikeNGladstone